1.3.5 Proton pump inhibitors

ChoiceDrugDosage
1st choiceLansoprazole capsules 15mg, 30mgDoses (see BNF for full details):
·   GORD, 30mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed; maintenance 15-30mg daily
·   Benign gastric ulcer, 30mg daily in the morning for 8 weeks
·   Duodenal ulcer, 30mg daily in the morning for 4 weeks; maintenance 15mg daily
·   NSAID-associated duodenal or gastric ulcer, 30mg once daily for 4 weeks, continued for further 4 weeks if not fully healed; prophylaxis, 15-30mg once daily
·   Acid-related dyspepsia, 15 to 30mg daily in the morning for 2 to 4 weeks
or
Omeprazole capsules 10mg, 20mg ·   GORD, 20mg once daily for 4 weeks, continued for further 4-8 weeks if not fully healed; 40mg once daily has been given for 8 weeks in GORD refractory to other treatment; maintenance 20mg once daily
·   Benign gastric and duodenal ulcers, 20mg once daily for 4 weeks in duodenal ulceration or 8 weeks in gastric ulceration; in severe or recurrent cases increase to 40mg daily
·   NSAID-associated duodenal or gastric ulcer and gastroduodenal erosions, 20mg once daily for 4 weeks, continued for further 4 weeks if not fully healed; prophylaxis in patients with a history of NSAID-associated duodenal or gastric ulcers, gastroduodenal lesions, or dyspeptic symptoms who require continued NSAID treatment, 20mg once daily
·   Acid-related dyspepsia, 10-20mg once daily for 2 to 4 weeks

Prescribing Notes

  • Refer to NICE clinical guideline on Dyspepsia and gastro‑oesophageal reflux disease (2014) here.
  • Omeprazole capsules should be prescribed rather than tablets. Tablets are a more expensive formulation with no additional benefit.
  • When initiating a PPI, the duration of treatment should be specified where possible, preferably by stating an end date or need for long term continuation of the medicine in the directions of the prescription.
  • With the exception of people with Barrett’s Oesophagus, PPIs should be ‘stepped down’ to the minimum dose that maintains symptom control in suitable patients. If the need for ongoing therapy is not reviewed, patients may continue to take unnecessarily high doses of PPIs or continue treatment beyond therapeutic need and may, therefore, be at risk of adverse effects associated with long-term use (see cautions box). Refer to stepdown SOP on primary care intranet.
  • Orodispersible tablets should be reserved for patients with swallowing difficulties or who require a PPI via a naso-gastric (NG) or percutaneous endoscopic gastrostomy (PEG) tube. If an orodispersible tablet is required, lansoprazole orodispersible is the preferred choice.
  • Lansoprazole and omeprazole suspensions are available from ‘special-order’ manufacturers. These preparations are unlicensed, very expensive and there are bioavailability differences between suspensions and other oral dose presentations. They should be reserved for patients with narrow bore feeding tubes at risk of blockage. Where a suspension is required, omeprazole 10mg/5ml oral suspension (Quzole powder and diluent for oral suspension) is available at a competitive price from Victoria Pharmaceuticals (ordered via Movianto Northern Ireland) – see ‘specials’ section for further information.
  • Prescribing on an ‘as required’ basis should be considered for patients with intermittent symptoms. Neither lansoprazole or omeprazole are licensed for ‘as required’ use but are frequently used for this indication and there is emerging evidence on the efficacy of on-demand therapy.
  • PPIs should be taken 30 to 60 minutes before food as there is better acid suppression when taken before a meal than without a meal.
  • An interaction between PPIs and clopidogrel leading to reduction of antiplatelet effect has been reported, but the clinical significance is uncertain. If co-prescribing a PPI with clopidogrel is thought necessary, lansoprazole is currently preferred to omeprazole or esomeprazole – see MHRA.

Cautions

  • PPIs might mask the symptoms of gastric cancer. Particular care is required in patients presenting with “alarm features”. In such cases gastric malignancy should be ruled out before treatment.
  • PPIs should be used with caution in the elderly as they are more susceptible to adverse effects.
  • There are concerns about the long term treatment with PPIs. The MHRA has issued safety advice on the long term use of PPIs and the following adverse effects:
  • Subacute cutaneous lupus erythematosus has been reported with PPIs (MHRA link).
  • Both lansoprazole and omeprazole interact with warfarin. Caution is required with concomitant use.